Sustained measles transmission across multiple states, fueled by declining MMR vaccination coverage and clustering in underimmunized communities, has driven 3,134 confirmed U.S. cases through early September 2026 according to CDC data—already exceeding the full-year 2025 total of 2,289 and marking the highest annual count since 1991. Approximately 95% of cases link to 38 ongoing or carryover outbreaks, with 94% occurring in individuals unvaccinated or of unknown status and 8% requiring hospitalization. CDC weekly surveillance updates and state reports on case counts, outbreak resolution, and any shifts in vaccination rates will continue to shape market-implied odds through year-end, alongside potential reviews of elimination status by health authorities.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourCas de rougeole aux États-Unis en 2026 ?
Cas de rougeole aux États-Unis en 2026 ?
$7,887,548 Vol.
$7,887,548 Vol.
31 déc. 2026
↑3,5k
98%
↑4k
94%
↑4,5k
89%
↑4,5k
77%
↑5k
54%
↑7,5k
13%
↑10k
6%
↑12,5k
2%
$7,887,548 Vol.
$7,887,548 Vol.
31 déc. 2026
↑3,5k
$14,848 Vol.
98%
↑4k
$240,467 Vol.
94%
↑4,5k
$2,197 Vol.
89%
↑4,5k
$202 Vol.
77%
↑5k
$239,658 Vol.
54%
↑7,5k
$191,100 Vol.
13%
↑10k
$6,522,777 Vol.
6%
↑12,5k
$356,344 Vol.
2%
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.Sustained measles transmission across multiple states, fueled by declining MMR vaccination coverage and clustering in underimmunized communities, has driven 3,134 confirmed U.S. cases through early September 2026 according to CDC data—already exceeding the full-year 2025 total of 2,289 and marking the highest annual count since 1991. Approximately 95% of cases link to 38 ongoing or carryover outbreaks, with 94% occurring in individuals unvaccinated or of unknown status and 8% requiring hospitalization. CDC weekly surveillance updates and state reports on case counts, outbreak resolution, and any shifts in vaccination rates will continue to shape market-implied odds through year-end, alongside potential reviews of elimination status by health authorities.
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
Marché ouvert : Jun 30, 2026, 2:17 PM ET
Volume
$7,887,548Date de fin
1 janv. 2027Marché ouvert
Jun 30, 2026, 2:17 PM ETRésolveur
0x65070BE91...This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.Sustained measles transmission across multiple states, fueled by declining MMR vaccination coverage and clustering in underimmunized communities, has driven 3,134 confirmed U.S. cases through early September 2026 according to CDC data—already exceeding the full-year 2025 total of 2,289 and marking the highest annual count since 1991. Approximately 95% of cases link to 38 ongoing or carryover outbreaks, with 94% occurring in individuals unvaccinated or of unknown status and 8% requiring hospitalization. CDC weekly surveillance updates and state reports on case counts, outbreak resolution, and any shifts in vaccination rates will continue to shape market-implied odds through year-end, alongside potential reviews of elimination status by health authorities.
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026 according to the CDC case counter between January 1, 2026, 12:00 AM ET and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
The resolution source for this market will be the CDC Measles (Rubeola) counter (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.
Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
Volume
$7,887,548Date de fin
1 janv. 2027Marché ouvert
Jun 30, 2026, 2:17 PM ETRésolveur
0x65070BE91...Sustained measles transmission across multiple states, fueled by declining MMR vaccination coverage and clustering in underimmunized communities, has driven 3,134 confirmed U.S. cases through early September 2026 according to CDC data—already exceeding the full-year 2025 total of 2,289 and marking the highest annual count since 1991. Approximately 95% of cases link to 38 ongoing or carryover outbreaks, with 94% occurring in individuals unvaccinated or of unknown status and 8% requiring hospitalization. CDC weekly surveillance updates and state reports on case counts, outbreak resolution, and any shifts in vaccination rates will continue to shape market-implied odds through year-end, alongside potential reviews of elimination status by health authorities.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes